- Home
- KURA vs CGEM Comparison
KURA vs CGEM Comparison
Compare KURA & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KURA | CGEM |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 830.1M | 671.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | KURA | CGEM |
|---|---|---|
| Price | $8.13 | $11.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | $26.88 | ★ $28.13 |
| AVG Volume (30 Days) | ★ 1.4M | 683.9K |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $104,029,000.00 | N/A |
| Revenue This Year | $88.72 | N/A |
| Revenue Next Year | $76.50 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.41 | $5.68 |
| 52 Week High | $12.49 | $13.33 |
Technical Indicators
Market Signals| Indicator | KURA | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 35.20 | 58.81 |
| Support Level | $8.02 | $11.53 |
| Resistance Level | $9.18 | $12.74 |
| Average True Range (ATR) | 0.41 | 0.73 |
| MACD | -0.04 | 0.07 |
| Stochastic Oscillator | 13.48 | 65.42 |
Price Performance
Historical ComparisonAbout KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.